Exposure‐Response Relationships for Efficacy and Safety of Filgotinib and its metabolite GS‐829845 in Subjects with Rheumatoid Arthritis Based on Phase 2 and Phase 3 Studies - Meng - - British Journal of Clinical Pharmacology - Wiley Online Library
Filgotinib is a potent, oral, JAK1-preferential inhibitor for the treatment of rheumatoid arthritis (RA). This report describes exposure-response (ER) analyses of filgotinib for dose confirmation based on three Phase 3 and two Phase 2 studies in moderate to severe RA patients. To read the full article, log in using your NHS OpenAthens details.
